{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:51:49Z","timestamp":1785538309368,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T00:00:00Z","timestamp":1413504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12941-014-0049-x","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T06:01:21Z","timestamp":1413439281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome"],"prefix":"10.1186","volume":"13","author":[{"given":"Doron","family":"Boltin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsachi Tsadok","family":"Perets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einav","family":"Shporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Aizic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Niv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Dickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,17]]},"reference":[{"key":"49_CR1","first-page":"112","volume":"3","author":"AC Dukowicz","year":"2007","unstructured":"Dukowicz AC, Lacy BE, Levine GM: Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007, 3: 112-122.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"49_CR2","doi-asserted-by":"crossref","unstructured":"Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 1999, 116: 1461-1463. 10.1016\/S0016-5085(99)70512-3.","DOI":"10.1016\/S0016-5085(99)70512-3"},{"key":"49_CR3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5056\/jnm.2011.17.3.312","volume":"17","author":"UC Ghoshal","year":"2011","unstructured":"Ghoshal UC: How to interpret hydrogen breath tests. J Neurogastroenterol Motil. 2011, 17: 312-317. 10.5056\/jnm.2011.17.3.312.","journal-title":"J Neurogastroenterol Motil"},{"key":"49_CR4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1572-0241.2003.07946.x","volume":"98","author":"M Pimentel","year":"2003","unstructured":"Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003, 98: 412-419.","journal-title":"Am J Gastroenterol"},{"key":"49_CR5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CEG.S18051","volume":"4","author":"J Jolley","year":"2011","unstructured":"Jolley J: High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol. 2011, 4: 43-48. 10.2147\/CEG.S18051.","journal-title":"Clin Exp Gastroenterol"},{"key":"49_CR6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cgh.2009.12.022","volume":"8","author":"L Lombardo","year":"2010","unstructured":"Lombardo L, Foti M, Ruggia O, Chiecchio A: Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010, 8: 504-508. 10.1016\/j.cgh.2009.12.022.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"49_CR7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/apt.12087","volume":"36","author":"P Meyrat","year":"2012","unstructured":"Meyrat P, Safroneeva E, Schoepfer AM: Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther. 2012, 36: 1084-1093. 10.1111\/apt.12087.","journal-title":"Aliment Pharmacol Ther"},{"key":"49_CR8","first-page":"89","volume":"52","author":"L Cuoco","year":"2006","unstructured":"Cuoco L, Salvagnini M: Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006, 52: 89-95.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"49_CR9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MAJ.0b013e3180536784","volume":"333","author":"M Majewski","year":"2007","unstructured":"Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW: Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci. 2007, 333: 266-270. 10.1097\/MAJ.0b013e3180536784.","journal-title":"Am J Med Sci"},{"key":"49_CR10","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.3748\/wjg.15.2628","volume":"15","author":"S Peralta","year":"2009","unstructured":"Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A: Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol. 2009, 15: 2628-2631. 10.3748\/wjg.15.2628.","journal-title":"World J Gastroenterol"},{"key":"49_CR11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cgh.2009.06.031","volume":"7","author":"AC Ford","year":"2009","unstructured":"Ford AC, Spiegel BM, Talley NJ, Moayyedi P: Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009, 7: 1279-1286. 10.1016\/j.cgh.2009.06.031.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"49_CR12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","volume":"107","author":"SB Menees","year":"2012","unstructured":"Menees SB, Maneerattannaporn M, Kim HM, Chey WD: The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012, 107: 28-35. 10.1038\/ajg.2011.355. quiz 36","journal-title":"Am J Gastroenterol"},{"key":"49_CR13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/apt.12456","volume":"38","author":"E Grace","year":"2013","unstructured":"Grace E, Shaw C, Whelan K, Andreyev HJ: Review article: small intestinal bacterial overgrowth-prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013, 38: 674-688. 10.1111\/apt.12456.","journal-title":"Aliment Pharmacol Ther"},{"key":"49_CR14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MEG.0b013e32801140e2","volume":"19","author":"AD Sperber","year":"2007","unstructured":"Sperber AD, Shvartzman P, Friger M, Fich A: A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the ???true??? prevalence of irritable bowel syndrome?. Eur J Gastroenterol Hepatol. 2007, 19: 441-447. 10.1097\/MEG.0b013e32801140e2.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"49_CR15","first-page":"1795","volume":"91","author":"SM Riordan","year":"1996","unstructured":"Riordan SM, McIver CJ, Walker BM, Duncombe VM, Bolin TD, Thomas MC: The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol. 1996, 91: 1795-1803.","journal-title":"Am J Gastroenterol"},{"key":"49_CR16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000103892","volume":"25","author":"A Gasbarrini","year":"2007","unstructured":"Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G: Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis. 2007, 25: 237-240. 10.1159\/000103892.","journal-title":"Dig Dis"},{"key":"49_CR17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-2036.2005.02690.x","volume":"22","author":"A Lupascu","year":"2005","unstructured":"Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005, 22: 1157-1160. 10.1111\/j.1365-2036.2005.02690.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"49_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2005.02516.x","volume":"22","author":"EC Lauritano","year":"2005","unstructured":"Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A: Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005, 22: 31-35. 10.1111\/j.1365-2036.2005.02516.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"49_CR19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/13543780902780175","volume":"18","author":"M Pimentel","year":"2009","unstructured":"Pimentel M: Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009, 18: 349-358. 10.1517\/13543780902780175.","journal-title":"Expert Opin Investig Drugs"},{"key":"49_CR20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","volume":"49","author":"JC Gillis","year":"1995","unstructured":"Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995, 49: 467-484. 10.2165\/00003495-199549030-00009.","journal-title":"Drugs"},{"key":"49_CR21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"M Pimentel","year":"2011","unstructured":"Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011, 364: 22-32. 10.1056\/NEJMoa1004409.","journal-title":"N Engl J Med"},{"key":"49_CR22","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1021\/es304367t","volume":"47","author":"GH Reischer","year":"2013","unstructured":"Reischer GH, Ebdon JE, Bauer JM, Schuster N, Ahmed W, Astr\u00f6m J, Blanch AR, Bl\u00f6schl G, Byamukama D, Coakley T, Ferguson C, Goshu G, Ko G, de Roda Husman AM, Mushi D, Poma R, Pradhan B, Rajal V, Schade MA, Sommer R, Taylor H, Toth EM, Vrajmasu V, Wuertz S, Mach RL, Farnleitner AH: Performance Characteristics of qPCR Assays Targeting Human- and Ruminant-Associated Bacteroidetes for Microbial Source Tracking across Sixteen Countries on Six Continents. Environ Sci Technol. 2013, 47: 8548-8556. 10.1021\/es304367t.","journal-title":"Environ Sci Technol"},{"key":"49_CR23","first-page":"1314","volume":"17","author":"E Scarpellini","year":"2013","unstructured":"Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundar\u00f2 C, Gasbarrini A: Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013, 17: 1314-1320.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"49_CR24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MPG.0b013e3181effa3b","volume":"52","author":"BS Collins","year":"2011","unstructured":"Collins BS, Lin HC: Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr. 2011, 52: 382-386. 10.1097\/MPG.0b013e3181effa3b.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"49_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1185\/0300799009117003","volume":"16","author":"L Biancone","year":"2000","unstructured":"Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F, Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F: Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin. 2000, 16: 14-20. 10.1185\/0300799009117003.","journal-title":"Curr Med Res Opin"},{"key":"49_CR26","first-page":"766","volume":"116","author":"A Stoicescu","year":"2012","unstructured":"Stoicescu A, Andrei M, Becheanu G, Stoicescu M, Nicolaie T, Diculescu M: Microscopic colitis and small intestinal bacterial overgrowth-diagnosis behind the irritable bowel syndrome?. Rev Med Chir Soc Med Nat Iasi. 2012, 116: 766-772.","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"49_CR27","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s10620-011-1719-6","volume":"56","author":"MS Chang","year":"2011","unstructured":"Chang MS, Minaya MT, Cheng J, Connor BA, Lewis SK, Green PH: Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Dig Dis Sci. 2011, 56: 2939-2946. 10.1007\/s10620-011-1719-6.","journal-title":"Dig Dis Sci"},{"key":"49_CR28","first-page":"1582","volume":"49","author":"L Cuoco","year":"2002","unstructured":"Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, Gasbarrini G: Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology. 2002, 49: 1582-1586.","journal-title":"Hepatogastroenterology"},{"key":"49_CR29","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.3748\/wjg.v11.i18.2773","volume":"11","author":"A Tursi","year":"2005","unstructured":"Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol. 2005, 11: 2773-2776.","journal-title":"World J Gastroenterol"},{"key":"49_CR30","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1572-0241.2007.01758.x","volume":"103","author":"A Parodi","year":"2008","unstructured":"Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, Savarino E, Indiveri F, Savarino V, Ghio M: Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008, 103: 1257-1262. 10.1111\/j.1572-0241.2007.01758.x.","journal-title":"Am J Gastroenterol"},{"key":"49_CR31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1365-2036.2010.04436.x","volume":"32","author":"M Furnari","year":"2010","unstructured":"Furnari M, Parodi A, Gemignani L, Giannini EG, Marenco S, Savarino E, Assandri L, Fazio V, Bonfanti D, Inferrera S, Savarino V: Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2010, 32: 1000-1006. 10.1111\/j.1365-2036.2010.04436.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"49_CR32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/15748847113089990048","volume":"8","author":"R Rosania","year":"2013","unstructured":"Rosania R, Giorgio F, Principi M, Amoruso A, Monno R, Di Leo A, Ierardi E: Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol. 2013, 8: 169-172. 10.2174\/15748847113089990048.","journal-title":"Curr Clin Pharmacol"},{"key":"49_CR33","first-page":"297","volume":"45","author":"PF Bayeli","year":"1999","unstructured":"Bayeli PF, Mariottini M, Lisi L, Ferrari P, Tedone F: Linee guida sul dismicrobismo intestinale (SIBO: Small Intestinal Bacterial Overgrowth). Minerva Gastroenterol Dietol. 1999, 45: 297-308.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"49_CR34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/gut.2009.205476","volume":"60","author":"D Yu","year":"2011","unstructured":"Yu D, Cheeseman F, Vanner S: Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011, 60: 334-340. 10.1136\/gut.2009.205476.","journal-title":"Gut"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-014-0049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12941-014-0049-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-014-0049-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T22:40:09Z","timestamp":1553640009000},"score":1,"resource":{"primary":{"URL":"http:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-014-0049-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,17]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1186\/s12941-014-0049-x","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,17]]},"article-number":"49"}}